AUTHORS

Real Money authors - Debra Borchardt

Debra Borchardt

Debra Borchardt is the CEO and Editor-In-Chief of the cannabis financial news site Green Market Report. She is an award-winning journalist who has covered the cannabis industry for the last seven years. Debra is often a panel guest or moderator at cannabis conferences and is considered a thought leader in the industry. She has appeared on Yahoo Finance TV, Cheddar TV and Bold TV to speak about the financial aspects of the industry. 

Email Debra Borchardt

Recent Articles By The Author

Is Psilocybin the New CBD?

As psychedelic medicines begin to become decriminalized, psilocybin seems to be leading the way in this category.

Compass Pathways Takes Investors on a Trip to Higher Prices

Fresh off IPO, company sees mushrooming opportunity in psilocybin.

The Promise of Hemp Begins to Fade

There are huge problems now plaguing the industry, which was just beginning to recover from last year's oversupply issues.

Capital Raising in Cannabis Falls 67%

Only five companies went public during the first half of 2020 versus 13 in the first half of 2019.

Vape Recovery Goes Up in Smoke Amid Pandemic

Following widely reported lung injuries and bans, the products struggle to come back as concerns over Covid-19 burn on.

Are Harvest Health's Legal Problems a Red Flag?

While HRVSF has navigated through numerous changes and delivered solid revenue, litigation issues are piling up.

GrowGeneration on a Tear as the Cannabis Field Expands

GRWG has no meaningful competition. The companies in the space are one-third the size and not competing on the same national scale.

Saw Your Investments Go to Pot? Consider Cannabis Tech

Here are two tech-infused names to watch this year.

Canaccord Genuity Raises U.S. Cannabis Sales Outlook

Many in the cannabis industry have been surmising that states will look to cannabis to plug any budget shortfalls.

Will Mydecine's Move Make the Market for Pharmaceutical Psilocybin Mushroom?

Psychedelic companies hoping to capitalize on a surging interest in psilocybin treatments have been limited to one source for research grade psilocybin. Until now.

Email sent

Thank you, your email to has been sent successfully.

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight